Edition:
India

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

204.65USD
1:30am IST
Change (% chg)

$1.99 (+0.98%)
Prev Close
$202.66
Open
$202.50
Day's High
$209.24
Day's Low
$201.51
Volume
710,828
Avg. Vol
510,788
52-wk High
$256.78
52-wk Low
$184.58

Chart for

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $67,750.49
Shares Outstanding(Mil.): 334.31
Dividend: 0.70
Yield (%): 1.38

Financials

  Industry Sector
P/E (TTM): -- 30.89 16.23
EPS (TTM): -- -- --
ROI: -- 14.28 15.24
ROE: -- 15.57 13.84

Native American tribe moves to dismiss Allergan patent case

A Native American tribe holding patents for drugmaker Allergan Plc on Friday moved to dismiss a case brought by generic drug company Mylan NV challenging the patents.

12:34am IST

UPDATE 1-Native American tribe moves to dismiss Allergan patent case

Sept 22 A Native American tribe holding patents for drugmaker Allergan Plc on Friday moved to dismiss a case brought by generic drug company Mylan NV challenging the patents.

12:30am IST

Native American tribe moves to dismiss Allergan patent case

Sept 22 A Native American tribe holding patents for drugmaker Allergan Plc on Friday moved to dismiss a case brought by generic drug company Mylan NV challenging the patents.

12:00am IST

BRIEF-Allergan Plc says new data from phase 2b study supports continued development of cenicriviroc in ongoing phase 3 trial

* New data from CENTAUR phase 2b clinical study supports continued development of cenicriviroc (CVC) in ongoing phase 3 AURORA trial

22 Sep 2017

U.S. senator slams Allergan patent deal with Native-American tribe

U.S. Senator Sherrod Brown said on Friday a deal that drugmaker Allergan Plc made with a Native-American tribe to shield patents "rips off consumers" and cannot "become the new normal."

15 Sep 2017

UPDATE 2-U.S. senator slams Allergan patent deal with Native-American tribe

Sept 15 U.S. Senator Sherrod Brown said on Friday a deal that drugmaker Allergan Plc made with a Native-American tribe to shield patents "rips off consumers" and cannot "become the new normal."

15 Sep 2017

U.S. senator slams Allergan tribal patent deal

Sept 15 U.S. Senator Sherrod Brown said on Friday a deal Allergan Plc made with a Native American tribe to shield its patents "rips off consumers" and cannot "become the new normal."

15 Sep 2017

REFILE-Challenge of Allergan tribal patent deal in uncharted legal territory

(Fixes date in dateline) By Jan Wolfe Sept 14 As generic drug manufacturers are gearing up to argue that a deal Allergan Plc made with a Native American tribe to shield patents from administrative review is a sham, some experts say the generic companies are in uncharted legal territory. Last week, Allergan announced it would transfer the patent rights to its Restasis dry-eye treatment to the Saint Regis Mohawk Tribe, which will license them back to the company i

15 Sep 2017

Challenge of Allergan tribal patent deal in uncharted legal territory

As generic drug manufacturers are gearing up to argue that a deal Allergan Plc made with a Native American tribe to shield patents from administrative review is a sham, some experts say the generic companies are in uncharted legal territory.

15 Sep 2017

Tech entity has tribal patent deal similar to Allergan's

The Native American tribe that agreed to hold patents for the drug company Allergan Plc in an attempt to shield them from U.S. administrative review is also doing so for a technology firm.

13 Sep 2017

Earnings vs. Estimates